Lumos Pharma Statistics
Share Statistics
Lumos Pharma has 8.65M shares outstanding. The number of shares has increased by 2.38% in one year.
| Shares Outstanding | 8.65M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.09% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 5.80M |
| Failed to Deliver (FTD) Shares | 652 |
| FTD / Avg. Volume | 0.7% |
Short Selling Information
The latest short interest is 86.38K, so 1% of the outstanding shares have been sold short.
| Short Interest | 86.38K |
| Short % of Shares Out | 1% |
| Short % of Float | 1.54% |
| Short Ratio (days to cover) | 0.92 |
Valuation Ratios
The PE ratio is -0.76 and the forward PE ratio is -2.02.
| PE Ratio | -0.76 |
| Forward PE | -2.02 |
| PS Ratio | 12.63 |
| Forward PS | 42.1 |
| PB Ratio | 0.95 |
| P/FCF Ratio | -0.83 |
| PEG Ratio | n/a |
Enterprise Valuation
Lumos Pharma Inc. has an Enterprise Value (EV) of -2.59M.
| EV / Earnings | 0.08 |
| EV / Sales | -1.26 |
| EV / EBITDA | 0.07 |
| EV / EBIT | 0.07 |
| EV / FCF | 0.08 |
Financial Position
The company has a current ratio of 5.69, with a Debt / Equity ratio of 0.01.
| Current Ratio | 5.69 |
| Quick Ratio | 5.69 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 1.02 |
| Cash Flow / Debt | -110.27 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.25% and return on capital (ROIC) is -131.17%.
| Return on Equity (ROE) | -1.25% |
| Return on Assets (ROA) | -0.84% |
| Return on Capital (ROIC) | -131.17% |
| Revenue Per Employee | 68.37K |
| Profits Per Employee | -1.13M |
| Employee Count | 30 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -29.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 52.28% in the last 52 weeks. The beta is 0.33, so Lumos Pharma 's price volatility has been higher than the market average.
| Beta | 0.33 |
| 52-Week Price Change | 52.28% |
| 50-Day Moving Average | 4.19 |
| 200-Day Moving Average | 3.08 |
| Relative Strength Index (RSI) | 55.58 |
| Average Volume (20 Days) | 93.03K |
Income Statement
In the last 12 months, Lumos Pharma had revenue of $2.05M and earned -$34.03M in profits. Earnings per share was $-4.18.
| Revenue | 2.05M |
| Gross Profit | 2.05M |
| Operating Income | -36.61M |
| Net Income | -34.03M |
| EBITDA | -36.57M |
| EBIT | -36.61M |
| Earnings Per Share (EPS) | -4.18 |
Balance Sheet
The company has $35.08M in cash and $585.00K in debt, giving a net cash position of $34.49M.
| Cash & Cash Equivalents | 35.08M |
| Total Debt | 585.00K |
| Net Cash | 34.49M |
| Retained Earnings | -161.52M |
| Total Assets | 17.46M |
| Working Capital | 10.77M |
Cash Flow
In the last 12 months, operating cash flow was -$31.09M and capital expenditures $0, giving a free cash flow of -$31.09M.
| Operating Cash Flow | -31.09M |
| Capital Expenditures | 0 |
| Free Cash Flow | -31.09M |
| FCF Per Share | -3.82 |
Margins
Gross margin is 100%, with operating and profit margins of -1.79K% and -1.66K%.
| Gross Margin | 100% |
| Operating Margin | -1.79K% |
| Pretax Margin | -1.66K% |
| Profit Margin | -1.66K% |
| EBITDA Margin | -1.78K% |
| EBIT Margin | -1.79K% |
| FCF Margin | -1.52K% |
Dividends & Yields
LUMO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -96.31% |
| FCF Yield | -82.84% |
Analyst Forecast
The average price target for LUMO is $8.62, which is 98.6% higher than the current price. The consensus rating is "Hold".
| Price Target | $8.62 |
| Price Target Difference | 98.6% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Mar 19, 2020. It was a backward split with a ratio of 1:9.
| Last Split Date | Mar 19, 2020 |
| Split Type | backward |
| Split Ratio | 1:9 |
Scores
| Altman Z-Score | -19.2 |
| Piotroski F-Score | 3 |